Artemis Medicare Soars 14% on Heavy Volume, Up 87% Since April Low

Artemis Medicare’s Share Price Surge Signals Strong Growth Potential

The remarkable rise in Artemis Medicare’s stock reflects robust business fundamentals and strategic expansion plans.

Key Drivers Behind the Surge

Artemis Medicare’s recent performance can be attributed to several key factors. The company operates over 800 beds in the Delhi NCR region, including a major quaternary care facility that has seen improved occupancy rates and higher average revenue per occupied bed (ARPOB). This growth is further supported by sustained demand across its specialized clinical services.

Additionally, the commencement of operations at its new Raipur hospital in July 2026 marks a significant expansion into high-growth markets, enhancing the company’s regional presence and long-term growth strategy. The management’s optimism is reflected in their Q1 earnings call, where they noted continued demand from international markets, particularly in the Middle East and Africa, despite geopolitical challenges.

Analyst Recommendations and Future Outlook

InCred Equities has initiated coverage on Artemis Medicare with a ‘Buy’ recommendation and a target price of ₹437 per share. The brokerage values the company at an enterprise value (EV)/EBITDA multiple of 23x for FY28E, reflecting strong growth expectations. Analysts project a compound annual growth rate (CAGR) of 23% for revenue, 28% for EBITDA, and 28% for profit after tax from FY26 to FY28E, driven by operational bed additions and strategic expansions.

The anticipated growth in operational beds from 544 to around 1,000 by FY28E, along with the development of VIMHANS in Delhi, adds further visibility to the company’s future earnings potential. Additionally, the management has approved a ₹700 crore Qualified Institutional Placement (QIP) for further brownfield acquisitions, which could enhance growth prospects if executed effectively.

Market Performance and Investor Sentiment

Despite a generally weak market, Artemis Medicare’s stock has outperformed, rallying 40% in the current calendar year while the BSE Sensex has seen a 12% decline. The stock’s performance is a testament to investor confidence in the company’s business model and growth strategy, particularly in light of its recent operational successes and expansion plans.

The heavy trading volume, with 12.75 million equity shares changing hands, indicates strong market interest and suggests that investors are positioning themselves for potential future gains as the company continues to expand its footprint in the healthcare sector.

Key Highlights

• Artemis Medicare’s share price surged 14% to ₹378.40, hitting an all-time high.
• The stock has rebounded 87% from its 52-week low of ₹202.85 in April 2026.
• InCred Equities has set a target price of ₹437, reflecting strong growth expectations.
• The company is expanding its operational beds from 544 to approximately 1,000 by FY28E.
• Heavy trading volume of 12.75 million shares indicates strong investor interest.
• Management plans to utilize ₹700 crore from a QIP for future acquisitions.

Investor Note: Investors should monitor Artemis Medicare’s expansion plans and operational performance closely, as these factors will be crucial in determining the stock’s future trajectory and overall market position.